4/A//SEC Filing
SUN PHARMA GLOBAL INC 4/A
Accession 0000947871-10-000973
CIK 0000906338other
Filed
Oct 4, 8:00 PM ET
Accepted
Oct 5, 3:11 PM ET
Size
24.0 KB
Accession
0000947871-10-000973
Insider Transaction Report
Form 4/AAmended
SUN PHARMA GLOBAL INC
10% OwnerOther
Transactions
- Purchase
Ordinary Shares
2010-10-01+2,333,922→ 9,338,168 total(indirect: See Footnote)
Alkaloida Chemical CO Exclusive Group Ltd.
10% OwnerOther
Transactions
- Purchase
Ordinary Shares
2010-10-01+2,333,922→ 9,338,168 total(indirect: See Footnote)
SUN PHARMACEUTICAL INDUSTRIES LTD
10% OwnerOther
Transactions
- Purchase
Ordinary Shares
2010-10-01+2,333,922→ 9,338,168 total(indirect: See Footnote)
Footnotes (4)
- [F1]Equivalent to Common Stock. All Ordinary Shares of Taro Pharmaceutical Industries Ltd. (the "Issuer") control in the aggregate two-thirds of the voting power of the Issuer.
- [F2]Upon the merger of a subsidiary of Sun Pharmaceutical Industries Inc. ("Sun Michigan"), a Michigan corporation and a direct subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun") with and into The Taro Development Corporation ("TDC") on October 1, 2010, for an aggregate consideration of approximately $18.1 million, Sun Michigan indirectly acquired 2,333,922 Ordinary Shares, consummating an option granted by TDC to Alkaloida Chemical Company Exclusive Group Ltd. ("Alkaloida"), an indirect subsidiary of Sun (and subsequently assigned to Sun Michigan) under an Option Agreement, dated May 17, 2007, among Sun, TDC, Dr. Barrie Levitt, Ms. Tal Levitt, Dr. Jacob Levitt, and Daniel Moros (such individuals, together with TDC, the "Grantors"). TDC directly owns 2,333,142 Ordinary Shares and indirectly owns 780 Ordinary Shares through Morley and Company, Inc., a New York corporation owned by TDC and Alkaloida.
- [F3]This amount represents 58,000 Ordinary Shares acquired by Sun Pharma Global, Inc. ("Sun Pharma"), a direct wholly-owned subsidiary of Sun, on July 11, 2007 and 500 Ordinary Shares acquired by Sun Pharma on July 23, 2007, in each case in open market transactions; 3,712,557 Ordinary Shares acquired by Alkaloida on February 19, 2008 from Brandes Investment Partners, L.P., for and on behalf of certain of its investment advisory clients; 797,870 Ordinary Shares acquired by Alkaloida on June 23, 2008 from Harel Insurance Company Limited; 29,382 Ordinary Shares acquired by Alkaloida on September 14, 2010 upon the expiration of the tender offer to acquire all of Issuer's outstanding Ordinary Shares, commenced on June 30, 2008; 2,405,937 Ordinary Shares acquired pursuant to a letter agreement, dated as of September 20, 2010, among Sun, Alkaloida, Sun Michigan and the Grantors; and 2,333,922 Ordinary Shares referenced in footnote 2.
- [F4]In addition, Sun indirectly owns 13,575,000 Ordinary Shares which are restricted stock consisting of: (i) 3,770,833 Ordinary Shares acquired by Alkaloida, on May 21, 2007 and 3,016,667 Ordinary Shares acquired by Alkaloida on May 30, 2007, in each case pursuant to the share purchase agreement dated May 18, 2007, between Alkaloida and the Issuer, which entitled Alkaloida to acquire a total of 7,500,000 Ordinary Shares; (ii) 3,000,000 Ordinary Shares acquired by Alkaloida on August 2, 2007, pursuant to Sun's rights under the warrant, dated May 18, 2007, issued by the Issuer to Sun, and (iii) 3,712,500 Ordinary Shares acquired by Alkaloida on September 24, 2010 and 75,000 Ordinary Shares acquired by Alkaloida on September 27, 2010, in each case pursuant to a warrant dated August 2, 2007, between Sun and the Issuer.
Issuer
TARO PHARMACEUTICAL INDUSTRIES LTD
CIK 0000906338
Entity typeother
Related Parties
1- filerCIK 0001197088
Filing Metadata
- Form type
- 4/A
- Filed
- Oct 4, 8:00 PM ET
- Accepted
- Oct 5, 3:11 PM ET
- Size
- 24.0 KB